Eligible asymptomatic individuals between the age range 40-50 years from the progression of early...
Author - Hippocrates Briefs Team
Hemodynamic Trial Study to Show Riociguat Outcomes In Patients...
The DYNAMIC trial study was a randomized, multicenter, placebo-controlled, double-blind IIB trial...
Study to Explore Cangrelor vs. Glycoprotein IIa/IIb Inhibitors...
During dual antiplatelet therapy, Cangrelor or eptifibatide, etc., short-acting parental...
Early Rhythm Control Therapy Effects With Atrial Fibrillation
This study was planned to collate clinical parameters and consequences in patients with different...
VISUALIZED: Early Rhythm Control Therapy Effects With Atrial...
Read further: Early Rhythm Control Therapy Effects With Atrial Fibrillation
Links Found Between COVID-19 Post-Recovery and Incident Heart...
To investigate the related events surrounding COVID-19 post-recovery and the development of de novo...
Improved Outcomes In Age-Irrespective Heart Failure and...
While it is known that empagliflozin plays a vital role in reducing cardiovascular death (CVD) or...
ARNI vs. ACEi In Reducing Heart Failure Events Post-Myocardial...
Angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) are drugs...
AHA Construct of Cardiovascular Health: Life’s Essential 8
The American Heart Association (AHA) worked on cardiovascular health, and in 2010 they defined a...
ACC Guidelines for Maternal Cardiovascular Care
The main purpose of the American College of Cardiology (ACC) is to change and recover the maternal...